MATINAS BIOPHARMA HOLDINGS, INC. Financials Matinas BioPharma Holdings, Inc.
Equities
MTNB
US5768101058
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.165 USD | -1.61% |
|
-4.40% | -23.68% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 369.4 | 271.5 | 218.4 | 108.4 | 46.97 | 41.38 | - | - |
| Enterprise Value (EV) 1 | 369.4 | 271.5 | 218.4 | 108.4 | 46.97 | 41.38 | 41.38 | 41.38 |
| P/E ratio | -17.5 x | -11.3 x | -9.18 x | -5 x | -1.97 x | -1.65 x | -1.5 x | -1.57 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 4,113 x | 1,715 x | 6,553 x | 34 x | 42.9 x | - | - | - |
| EV / Revenue | 4,113 x | 1,715 x | 6,553 x | 34 x | 42.9 x | - | - | - |
| EV / EBITDA | -19,739,195 x | -11,324,598 x | -8,918,203 x | -4,470,880 x | - | - | - | - |
| EV / FCF | -25,481,365 x | -15,627,904 x | -14,105,674 x | - | - | - | - | - |
| FCF Yield | -0% | -0% | -0% | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 162,740 | 199,642 | 216,248 | 216,865 | 217,265 | 250,816 | - | - |
| Reference price 2 | 2.270 | 1.360 | 1.010 | 0.5000 | 0.2162 | 0.1650 | 0.1650 | 0.1650 |
| Announcement Date | 3/9/20 | 3/29/21 | 3/8/22 | 3/15/23 | 3/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.0898 | 0.1583 | 0.0333 | 3.188 | 1.096 | - | - | - |
| EBITDA | -18.72 | -23.98 | -24.49 | -24.25 | - | - | - | - |
| EBIT 1 | -18.92 | -24.21 | -24.73 | -24.59 | -23.77 | -25.42 | -34.74 | -35.98 |
| Operating Margin | -21,067.85% | -15,288.67% | -74,211.7% | -771.33% | -2,168.43% | - | - | - |
| Earnings before Tax (EBT) 1 | -17.37 | -22.45 | -23.28 | -21 | -22.94 | -25.28 | -34.62 | -35.83 |
| Net income 1 | -18.3 | -23.24 | -23.68 | -21 | -22.94 | -25.25 | -34.62 | -35.83 |
| Net margin | -20,372.8% | -14,678.38% | -71,044.73% | -658.63% | -2,093.25% | - | - | - |
| EPS 2 | -0.1300 | -0.1200 | -0.1100 | -0.1000 | -0.1100 | -0.1000 | -0.1100 | -0.1050 |
| Free Cash Flow | -14.5 | -17.37 | -15.48 | - | - | - | - | - |
| FCF margin | -16,142.6% | -10,973.02% | -46,456.17% | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/9/20 | 3/29/21 | 3/8/22 | 3/15/23 | 3/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 1.062 | 1.062 | 1.063 | 1.096 | - | - | - | - | - | - | - |
| EBITDA | -6.649 | -7.653 | -5.84 | -5.373 | -5.387 | -5.493 | - | - | - | - | - | - | - |
| EBIT 1 | -6.714 | -7.722 | -5.925 | -5.463 | -5.48 | -5.586 | -6.159 | -6.134 | -5.887 | -5.902 | -5.98 | -6.51 | -7.04 |
| Operating Margin | - | - | -557.69% | -514.13% | -515.49% | -509.67% | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -6.699 | -5.978 | -5.923 | -5.462 | -3.635 | -5.513 | -6.06 | -6.055 | -5.314 | -5.824 | -5.956 | -6.486 | -7.016 |
| Net income 1 | -6.699 | -5.978 | -5.923 | -5.462 | -3.635 | -5.513 | -6.06 | -6.055 | -5.314 | -5.824 | -5.956 | -6.486 | -7.016 |
| Net margin | - | - | -557.42% | -514.03% | -341.91% | -503.01% | - | - | - | - | - | - | - |
| EPS 2 | -0.0300 | -0.0300 | -0.0300 | -0.0300 | -0.0200 | -0.0300 | -0.0300 | -0.0300 | -0.0300 | -0.0300 | -0.0267 | -0.0267 | -0.0267 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/8/22 | 5/12/22 | 8/11/22 | 11/2/22 | 3/15/23 | 5/10/23 | 8/9/23 | 11/8/23 | 3/27/24 | 5/9/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | -14.5 | -17.4 | -15.5 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | 0.41 | 0.01 | - | - | - | - | - | - |
| Capex / Sales | 451.62% | 3.63% | - | - | - | - | - | - |
| Announcement Date | 3/9/20 | 3/29/21 | 3/8/22 | 3/15/23 | 3/27/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.165
USD
Average target price
0.8667
USD
Spread / Average Target
+425.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.68% | 42.06M | |
| +10.79% | 115B | |
| +11.65% | 106B | |
| -6.20% | 24.69B | |
| -2.33% | 21.97B | |
| -6.03% | 19.27B | |
| -13.41% | 17.56B | |
| -40.50% | 17.32B | |
| +6.64% | 14.03B | |
| +31.84% | 12.13B |
- Stock Market
- Equities
- MTNB Stock
- Financials Matinas BioPharma Holdings, Inc.
